56.71

2.12% -1.23

After Hours: 56.60 -0.11 -0.19%

Scholar Rock Holding Corp (SRRK)

Overview News Price History Option Chain Financials Discussions Forecast

Scholar Rock Holding Corp stock is traded at $56.71, with a volume of 828.81K. It is down -2.12% in the last 24 hours and up +28.62% over the past month. Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

Previous Close:

$57.94

Open:

$57.245

24h Volume:

828.81K

Relative Volume:

0.57

Market Cap:

$6.80B

Revenue:

$47.30M

Net Income/Loss:

$-377.94M

P/E Ratio:

-16.55

EPS:

-3.4256

Net Cash Flow:

$-300.64M

1W Performance:

+3.33%

1M Performance:

+28.62%

6M Performance:

+34.45%

1Y Performance:

+48.79%

1-Day Range:

$55.14

$58.49

1-Week Range:

$54.00

$58.49

52-Week Range:

$27.07

$58.49

Scholar Rock Holding Corp Stock (SRRK) Company Profile

Name

Scholar Rock Holding Corp

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

857-259-3860

Address

301 BINNEY STREET, CAMBRIDGE, MA

Employee

289

Twitter

@ScholarRock

Next Earnings Date

2026-08-05

Latest SEC Filings

SRRK's Discussions on Twitter

Compare SRRK vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SRRK Scholar Rock Holding Corp	56.71	6.94B	47.30M	-377.94M	-300.64M	-3.4256
VRTX Vertex Pharmaceuticals Inc	485.39	126.01B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	70.03B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	56.56B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	40.63B	742.00K	-1.37B	-1.07B	-7.0731

Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Jan-09-26	Initiated	Citigroup	Buy
Nov-18-25	Initiated	Wolfe Research	Outperform
Oct-09-25	Initiated	BofA Securities	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Resumed	Jefferies	Buy
Jul-30-25	Resumed	Raymond James	Strong Buy
Jul-17-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Reiterated	H.C. Wainwright	Buy
Oct-07-24	Reiterated	H.C. Wainwright	Buy
Mar-28-24	Initiated	Raymond James	Strong Buy
Oct-25-23	Upgrade	Jefferies	Hold → Buy
Apr-03-23	Resumed	Piper Sandler	Overweight
Sep-19-22	Resumed	H.C. Wainwright	Buy
Jul-12-22	Initiated	Truist	Buy
Mar-23-22	Initiated	H.C. Wainwright	Buy
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Nov-19-21	Initiated	Piper Sandler	Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Jan-11-21	Initiated	Credit Suisse	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Mar-12-20	Initiated	Robert W. Baird	Outperform

View All

Scholar Rock Holding Corp Stock (SRRK) Latest News

Jul 09, 2026

SG Americas Securities LLC Cuts Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat

Jul 09, 2026

Jul 07, 2026

Inside THNR: A Leaner Approach to Weight Loss Investing - ETF Database

Jul 07, 2026

Scholar Rock stock hits 52-week high at 56.56 USD - Investing.com

Jul 07, 2026